Beijing Hotgen Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	111.78	536.84	282.05	276.11	523.49	1,161
Short-Term Investments	-	-	601.14	50	50.95	-
Trading Asset Securities	1,101	830.33	201.51	280.02	888.68	927.45
Cash & Short-Term Investments	1,213	1,367	1,085	606.13	1,463	2,089
Cash Growth	-0.69%	26.04%	78.95%	-58.57%	-29.94%	445.84%
Accounts Receivable	144.6	118.48	91.99	28.59	102.04	38.21
Other Receivables	3.86	1.36	4.15	28.93	17.01	47.36
Receivables	148.46	119.84	96.15	57.52	119.06	85.57
Inventory	59.6	79.36	85.56	137.21	154.25	258.62
Prepaid Expenses	-	-	-	0.15	2.6	-
Other Current Assets	64.98	30.62	41.71	38.9	59.24	84.98
Total Current Assets	1,486	1,597	1,308	839.91	1,798	2,518
Property, Plant & Equipment	869.61	902.19	1,081	1,193	867.94	562.12
Long-Term Investments	519.54	477.84	827.23	1,418	1,038	441.6
Other Intangible Assets	47.81	48.52	52.12	55.07	56.55	57.33
Long-Term Deferred Tax Assets	18.45	35.41	26.64	34.4	38.8	15.95
Long-Term Deferred Charges	17.66	20.15	25.77	24.3	23.2	22.32
Other Long-Term Assets	131.79	98.77	29.54	6.76	76.21	27.85
Total Assets	3,091	3,180	3,351	3,572	3,899	3,645

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	132.06	49.81	49.7	44.72	151.52	141.27
Accrued Expenses	22.11	38.66	32.67	25.55	177.68	167.53
Short-Term Debt	-	50.02	42.66	-	-	-
Current Portion of Leases	0.04	0.34	0.12	7.49	27.95	13
Current Income Taxes Payable	5.33	0.93	1.06	1.15	1.13	120.24
Current Unearned Revenue	14.96	13.14	16.7	28.08	56.98	267.05
Other Current Liabilities	46.1	95.15	141.91	81.05	96.06	25.08
Total Current Liabilities	220.59	248.03	284.81	188.04	511.31	734.16
Long-Term Leases	3.8	0.13	0.12	7.76	14.18	22.98
Long-Term Unearned Revenue	11.1	11.07	15.75	9.77	10.77	9.47
Long-Term Deferred Tax Liabilities	-	0.01	-	-	9.32	4.41
Other Long-Term Liabilities	264	264.05	-	-	-	-
Total Liabilities	499.49	523.29	300.69	205.57	545.59	771.01

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	92.71	92.71	92.47	92.27	92.05	62.2
Additional Paid-In Capital	171.09	163.82	334.61	444.04	435.31	458.31
Retained Earnings	2,477	2,545	2,761	2,994	2,958	2,323
Treasury Stock	-338.11	-338.55	-133.89	-166.48	-150.04	-
Comprehensive Income & Other	29.47	23.36	9.96	4.32	-0.03	-0.3
Total Common Equity	2,432	2,486	3,064	3,368	3,335	2,844
Minority Interest	159.58	170.32	-14.16	-2.12	18.46	30.31
Shareholders' Equity	2,592	2,657	3,050	3,366	3,354	2,874
Total Liabilities & Equity	3,091	3,180	3,351	3,572	3,899	3,645

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	3.84	50.49	42.9	15.26	42.13	35.98
Net Cash (Debt)	1,209	1,317	1,042	590.87	1,421	2,053
Net Cash Growth	3.25%	26.39%	76.31%	-58.42%	-30.77%	436.43%
Net Cash Per Share	13.16	14.38	11.95	6.69	15.46	22.30
Filing Date Shares Outstanding	88.39	87.93	89.58	89.41	89.53	92.05
Total Common Shares Outstanding	88.39	87.93	89.58	89.41	89.53	92.05
Working Capital	1,266	1,349	1,023	651.88	1,287	1,784
Book Value Per Share	27.52	28.28	34.20	37.67	37.25	30.89
Tangible Book Value	2,384	2,438	3,012	3,313	3,279	2,786
Tangible Book Value Per Share	26.97	27.72	33.62	37.06	36.62	30.27
Buildings	-	616.65	703.6	704.79	174.55	162.16
Machinery	-	543.25	581.09	575.66	399.88	317.94
Construction In Progress	-	0.12	5.62	48.18	374.44	121.71